The role of alternative splicing in lung cancer Xuelian NingZitong FuShuoshuo Wang Review Article 19 June 2023 Pages: 83 - 95
Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies Alexis C. BoulterBarry J. MaurerDavid E. Gerber Original Article 18 May 2023 Pages: 97 - 105
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation Sarina A. Piha-PaulChieh TsengFunda Meric-Bernstam Original Article Open access 14 June 2023 Pages: 107 - 118
Osthole inhibits malignant phenotypes and induces ferroptosis in KRAS-mutant colorectal cancer cells via suppressing AMPK/Akt signaling Xinghua ZhouJian KangYue Cheng Original Article 15 June 2023 Pages: 119 - 134
Influence of age on pharmacokinetics of capecitabine and its metabolites in older adults with cancer: a pilot study Mohsen ShafieiPeter GalettisPrunella Blinman Original Article 23 June 2023 Pages: 135 - 139
Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study Mats NågårdMei-Lin Ah-SeeGanesh M. Mugundu Original Article Open access 27 June 2023 Pages: 141 - 150
A case report of typhlitis during novel use of ropidoxuridine–capecitabine–radiotherapy for treatment-naïve rectal cancer Charles A. KunosRichard PiekarzTimothy J. Kinsella Clinical Trial Report Open access 27 June 2023 Pages: 151 - 155
Pharmacology and pharmacokinetics of elacestrant Jan H. BeumerJulia Foldi Short Communication 14 June 2023 Pages: 157 - 163